Unlocking antimicrobial potential of microalgae on food-borne bacteria: A standardized framework and future directions

• Microalgae represent a source of antimicrobial bioactives. • No antimicrobials from microalgae are currently commercially available. • Microalgal growth, bioactives extraction, and testing choices affect bioactivity. • Standardized framework for bioactivity testing is critically needed. • Future developments lie in the selection of sampling sites, omics and artificial intelligence. Foodborne infections are a global challenge, costing billions annually through food losses, trade restrictions, and healthcare expenses. Growing concerns over chemical antimicrobials such as antibiotics, sanitizers, and disinfectants, have driven interest in sustainable bio-control strategies for food systems. Microalgae, which produce a plethora of biomolecules including carbohydrates, lipids, proteins, and various secondary metabolites, represent a promising source of antimicrobial compounds. Despite numerous reports demonstrating antimicrobial activity in microalgal extracts, no microalgae-derived antimicrobials have yet reached commercialization. This review focuses on some microalgal species already produced at commercial scale, including those with GRAS status (e.g., Chlorella vulgaris and Chlamydomonas reinhardtii ). As for other microalgae-based products (e.g., biofuel oil), successful antimicrobial production depends on identifying key species and strains, optimizing growth conditions, and refining harvesting, cell disruption, and extraction protocols. Although research in this area is expanding, further studies are needed to improve our understanding of antimicrobials synthesis and to assess how these factors influence antimicrobial activity. Commonly used antibacterial assays such as disc diffusion and microdilution have limitations that must be considered when evaluating the antimicrobial activity of microalgal extracts. Overall, inconsistencies in testing and reporting have hindered the clear identification of microalgae as sources of effective antimicrobials. This review proposes a framework for future extract preparation and antimicrobial assessment and discusses future prospects to enhance the discovery and yield of microalgal antimicrobials.

Authors

Publication Details

Journal
Current Research in Biotechnology
Published
2025-12-24
DOI
https://doi.org/10.1016/j.crbiot.2025.100362
Primary Topic
Algal biology and biofuel production
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Unlocking antimicrobial potential of microalgae on food-borne bacteria: A standardized framework and future directions

Maxence Plouviez, Nigel French, Delphine Rapp, Dieke Schelvis
Current Research in Biotechnology
Algal biology and biofuel production
article

Unlocking antimicrobial potential of microalgae on food-borne bacteria: A standardized framework and future directions

Maxence Plouviez, Nigel French, Delphine Rapp, Dieke Schelvis
article en

Abstract

• Microalgae represent a source of antimicrobial bioactives. • No antimicrobials from microalgae are currently commercially available. • Microalgal growth, bioactives extraction, and testing choices affect bioactivity. • Standardized framework for bioactivity testing is critically needed. • Future developments lie in the selection of sampling sites, omics and artificial intelligence. Foodborne infections are a global challenge, costing billions annually through food losses, trade restrictions, and healthcare expenses. Growing concerns over chemical antimicrobials such as antibiotics, sanitizers, and disinfectants, have driven interest in sustainable bio-control strategies for food systems. Microalgae, which produce a plethora of biomolecules including carbohydrates, lipids, proteins, and various secondary metabolites, represent a promising source of antimicrobial compounds. Despite numerous reports demonstrating antimicrobial activity in microalgal extracts, no microalgae-derived antimicrobials have yet reached commercialization. This review focuses on some microalgal species already produced at commercial scale, including those with GRAS status (e.g., Chlorella vulgaris and Chlamydomonas reinhardtii ). As for other microalgae-based products (e.g., biofuel oil), successful antimicrobial production depends on identifying key species and strains, optimizing growth conditions, and refining harvesting, cell disruption, and extraction protocols. Although research in this area is expanding, further studies are needed to improve our understanding of antimicrobials synthesis and to assess how these factors influence antimicrobial activity. Commonly used antibacterial assays such as disc diffusion and microdilution have limitations that must be considered when evaluating the antimicrobial activity of microalgal extracts. Overall, inconsistencies in testing and reporting have hindered the clear identification of microalgae as sources of effective antimicrobials. This review proposes a framework for future extract preparation and antimicrobial assessment and discusses future prospects to enhance the discovery and yield of microalgal antimicrobials.

Current Research in BiotechnologyVol. 11
Responsible consumption and production
Openalex Percentile: Top 53%
Algal biology and biofuel production
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.